Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

1,678JPY
24 Oct 2014
Price Change (% chg)

¥43 (+2.63%)
Prev Close
¥1,636
Open
¥1,673
Day's High
¥1,690
Day's Low
¥1,670
Volume
3,648,800
Avg. Vol
2,472,765
52-wk High
¥2,007
52-wk Low
¥1,570

4568.T

Chart for 4568.T

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company has two business segments. The Daiichi Sankyo Group segment is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and... (more)

Overall

Beta: 0.67
Market Cap (Mil.): ¥1,159,588.00
Shares Outstanding (Mil.): 709.01
Dividend: 30.00
Yield (%): 3.67

Financials

  4568.T Industry Sector
P/E (TTM): 16.50 33.08 33.86
EPS (TTM): 99.12 -- --
ROI: 4.85 18.26 17.53
ROE: 7.47 18.93 18.34
Search Stocks

Japan's Daiichi Sankyo to acquire US biopharma Ambit Biosciences

TOKYO - Japanese drugmaker Daiichi Sankyo Co Ltd has agreed to acquire U.S. biopharmaceutical company Ambit Biosciences Corp in a deal valued up to $410 million as it looks to build its presence in oncology, the companies said.

28 Sep 2014

Japan's Daiichi Sankyo to acquire US biopharma Ambit Biosciences

TOKYO, Sept 29 - Japanese drugmaker Daiichi Sankyo Co Ltd has agreed to acquire U.S. biopharmaceutical company Ambit Biosciences Corp in a deal valued up to $410 million as it looks to build its presence in oncology, the companies said.

28 Sep 2014

INDIA PRESS-Sun Pharma banks on Daiichi Sankyo to crack Japan market-Economic Times

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Aby Jose Koilparambil in Bangalore)

10 Aug 2014

Update-Moody's affirms Daiichi Sankyo's A1 rating; outlook stable

For the full text of this story please click the following link:

02 Jun 2014

Targeted Plexxikon drug helps ease pain from rare joint disease

CHICAGO - An experimental cancer drug being developed by Plexxikon, a unit of Daiichi Sankyo, appears to ease pain and swelling in patients with a rare joint disease caused by a genetic mutation, researchers said on Wednesday.

14 May 2014

Targeted Plexxikon drug helps ease pain from rare joint disease

CHICAGO, May 14 - An experimental cancer drug being developed by Plexxikon, a unit of Daiichi Sankyo, appears to ease pain and swelling in patients with a rare joint disease caused by a genetic mutation, researchers said on Wednesday.

14 May 2014

INDIA PRESS-Daiichi Sankyo contests Andhra Pradesh High Court fiat on Ranbaxy deal-Economic Times

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Aby Jose Koilparambil in Bangalore)

11 May 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics Prime
$25.00
Provider: MarketLine (a Datamonitor Company)
$175.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks